Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 64 (4), 660-8

Recent Developments in the Psychopharmacology of Anxiety Disorders

Affiliations
Review

Recent Developments in the Psychopharmacology of Anxiety Disorders

R B Lydiard et al. J Consult Clin Psychol.

Abstract

Anxiety disorders are the most prevalent mental disorders in the United States. In the past 3 decades, substantial advances have been made in the ability to identify and treat anxiety disorders including panic disorder (PD), social phobia (SP), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). It is now known that these common, usually chronic disorders confer significant disability to untreated sufferers. This overview highlights some of the important advances in pharmacological treatment of anxiety disorders. Evidence for efficacy of the various pharmacological agents (including relevant oral dosing and plasma-level data) and of acute and long-term treatment, and the disadvantages of medication treatment are discussed. Finally, some important clinical questions remaining to be addressed by psychopharmacological research are reviewed.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

MeSH terms

Substances

Feedback